Series A

Ethyreal launches to treat the underlying cause of Graves’, TED

Thu, 11 Jun 2026 12:00:00 -0400

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.

IMU’s $53M series A to advance high-definition immune profiling tech

Wed, 03 Jun 2026 09:00:00 -0400

IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.

Tavo Biotherapeutics closes series A to advance ocular pipeline

Wed, 03 Jun 2026 09:00:00 -0400

Tavo Biotherapeutics Inc. has successfully closed a $17 million series A financing, with the proceeds directed to advancing the company’s pipeline of innovative therapies targeting glaucoma and retinal disease.

IMU’s $53M series A to advance high-definition immune profiling tech

Tue, 02 Jun 2026 12:00:00 -0400

Newco news: Oorja energizes with $30M for IPF

Fri, 22 May 2026 12:00:00 -0400

Oorja Bio Inc., named after the phonetic spelling of “energy” in Sanskrit, secured $30 million from founding investor Westlake Biopartners in a series A financing round to advance its in-licensing approach to develop drugs for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases.

Degron closes $40M series A to advance molecular glue degraders

Tue, 19 May 2026 12:00:00 -0400

Degron Therapeutics Inc. closed a $40 million series A extension round that will see the company advance its molecular glue degraders targeting previously undruggable or insufficiently drugged proteins.

Degron closes $40M series A to advance molecular glue degraders

Mon, 18 May 2026 12:00:00 -0400

Sonomind raises €20M for ultrasound neuromodulation technology

Fri, 15 May 2026 12:00:00 -0400

Sonomind SAS raised €20 million (US$23 million) in a series A funding round for its ultrasound-based neuromodulation technology for depression. The funds will be used for clinical trials of the non-invasive device, which uses a custom-made acoustic lens to precisely target deep regions within the brain to bring relief to patients suffering from treatment-resistant depression.

Sonire starts US study of cancer HIFU after $18M series A

Tue, 05 May 2026 12:00:00 -0400

Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.

Cytospire raises £61M series A to target EGFR in solid tumors

Tue, 05 May 2026 09:00:00 -0400

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the clinic in the treatment of EGFR-positive solid tumors. The company’s pan gamma delta (γδ) TCEs are designed to overcome problems with cytokine release syndrome, on-target effects on healthy cells, and the excessive activation of CD3 that have occurred with earlier bispecific antibodies that bind to the CD3 receptor on T cells.

Latus Bio series A financing supports early-stage programs

Mon, 04 May 2026 09:00:00 -0400

Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the financing are expected to fund operations through milestones that include initial clinical data from the company’s two most advanced programs: LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

Sonire starts US study of cancer HIFU after $18M series A

Fri, 01 May 2026 12:00:00 -0400

Financing supports Fathom Therapeutics’ Microcosmos drug design engine

Tue, 28 Apr 2026 09:00:00 -0400

Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed series A financing to advance its work using physics-based simulations and AI to model protein motion and interactions at atomic resolution.

Tortugas launches with $106M for neurology, neuropsychiatric drugs

Tue, 21 Apr 2026 12:00:00 -0400

Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.

Financing at Vivatides to advance extrahepatic RNA therapeutics

Mon, 13 Apr 2026 09:00:00 -0400

Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.

Realta secures another $40M for its hypoxic ischemic encephalopathy treatment

Fri, 10 Apr 2026 12:00:00 -0400

Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the total the company has raised to more than $150 million through mission-driven investors and a family-office model.

Stipple launches with $100M for novel oncology targets

Tue, 07 Apr 2026 09:00:00 -0400

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.

Stipple launches with $100M for novel oncology targets

Mon, 06 Apr 2026 12:00:00 -0400

Braveheart finds phase II positive for cardiac myosin inhibitor

Tue, 31 Mar 2026 12:00:00 -0400

Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study.

How to grow a startup in the AI era: MedTech Spotlight Korea 2026

Tue, 24 Mar 2026 12:00:00 -0400

AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.

Immutrin raises £65M series A to take another run at reversing amyloidosis

Tue, 24 Mar 2026 12:00:00 -0400

Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.

Financing at Immutrin to advance antibody for ATTR cardiomyopathy

Tue, 24 Mar 2026 09:00:00 -0400

Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.

How to grow a startup in the AI era: MedTech Spotlight Korea 2026

Mon, 23 Mar 2026 12:00:00 -0400

Oryon emerges with autologous stem cell therapy for Parkinson’s

Mon, 23 Mar 2026 12:00:00 -0400

Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases.

Series A financing at VST Bio to advance VB-001 into clinic

Wed, 18 Mar 2026 09:00:00 -0400

VST Bio Corp. has closed its series A financing designed to support the company’s work in vascular diseases with the development of first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke.

R1’s $77.5M series A to fund CKD trial of oral phosphate inhibitor

Tue, 17 Mar 2026 08:00:00 -0400

Newco R1 Therapeutics Inc. has launched with an oversubscribed $77.5 million series A, providing the means to take AP-306, a potentially first-in-class hyperphosphatemia therapy through phase IIb development in patients with chronic kidney disease.

‘Dial is stuck’ on progress in female leadership in UK biotech

Fri, 06 Mar 2026 12:00:00 -0500

One year on from establishing the baseline on female representation in the U.K. biotech industry, the latest survey shows the “dial is stuck.” Since the first report, representation at the CEO level has crept from 18.3% to 18.7%. That is “a marginal gain that signals a plateau at a time when we need a breakthrough,” said Jane Wall, managing director of the U.K. Bioindustry Association, which compiled the statistics.

Antiverse announces series A financing, tie-up with CF Foundation

Wed, 04 Mar 2026 08:00:00 -0500

Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.

Slate Medicines launches with focus on headache disorders

Wed, 25 Feb 2026 08:00:00 -0500

Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders.

New funding supports Centauri’s antimicrobial CTX-187

Tue, 24 Feb 2026 08:00:00 -0500

Centauri Therapeutics Ltd. has extended its series A financing round to £30 million (US$40.5 million) with the addition of a new £6 million (US$8 million) investment. Centauri initially closed its £24 million (US$32 million) series A round in 2022.